Stocks News

LAST PRICE
219.2300
TODAY'S CHANGE (%)
Trending Up1.5500 (0.7121%)

Bid / Lots
206.2600/ 1
Ask / Lots
256.7400/ 1
Open / Previous Close
217.4700 / 217.6800
Day Range
Low 216.7400
High 222.0400
52 Week Range
Low 190.2000
High 261.7300
Volume
1,418,430
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 6, 2024
- IQVIA CFO Ron Bruehlman to Speak at the UBS Global Healthcare Conference on November 13, 2024, from 4:15PM ET on Wednesday Nov 06, 2024 by Dow Jones
  4:15PM ET on Wednesday Nov 06, 2024 by Dow Jones
  Companies Mentioned: IQV
  
  IQVIA CFO Ron Bruehlman to Speak at the UBS Global Healthcare Conference on November 13, 2024
  RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--November 06, 2024--
  IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the UBS Healthcare Conference in Rancho Palos Verdes, California on Wednesday, November 13, 2024 at 1:15 p.m. ET.
- Argus Cuts Price Target on IQVIA to $260 From $280, from 7:53AM ET on Wednesday Nov 06, 2024 by MT Newswires
  7:53AM ET on Wednesday Nov 06, 2024 by MT Newswires
  Companies Mentioned: IQV
  07:53 AM EST, 11/06/2024 (MT Newswires) -- IQVIA Holdings Inc (IQV) has an average rating of outperform and price targets ranging from $195 to $290, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic rese...
Nov 5, 2024
- DJ IQVIA Holdings Price Target Maintained With a $270.00/Share by RBC Capital, from 11:34AM ET on Tuesday Nov 05, 2024 by Dow Jones
  11:34AM ET on Tuesday Nov 05, 2024 by Dow Jones
  Companies Mentioned: IQV
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/IQV/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 05, 2024 11:34 ET (16:34 GMT)
- DJ IQVIA Holdings Is Maintained at Overweight by JP Morgan, from 11:28AM ET on Tuesday Nov 05, 2024 by Dow Jones
  11:28AM ET on Tuesday Nov 05, 2024 by Dow Jones
  Companies Mentioned: IQV
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/IQV/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 05, 2024 11:28 ET (16:28 GMT)
- JPMorgan Cuts Price Target on IQVIA to $240 From $279, Maintains Overweight Rating, from 7:01AM ET on Tuesday Nov 05, 2024 by MT Newswires
  7:01AM ET on Tuesday Nov 05, 2024 by MT Newswires
  Companies Mentioned: IQV
  07:01 AM EST, 11/05/2024 (MT Newswires) -- IQVIA Holdings Inc (IQV) has an average rating of outperform and price targets ranging from $195 to $290, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic rese...

Yesterday
- S&P 500 Closes Just Shy of Record 6,000 Amid Strong Post-Election Rally, from 20 hours ago by MT Newswires
  20 hours ago by MT Newswires
  Companies Mentioned: HD, CSCO, SPGI, VTRS, TSLA, WBD, MRNA, AZN, PLTR, CE, DIS, MTCH
- DJ Moderna Is Maintained at Overweight by Barclays, from 23 hours ago by Dow Jones
  23 hours ago by Dow Jones
  Companies Mentioned: MRNA
- Jefferies Adjusts Moderna Price Target to $50 From $55, from 12:38PM ET on Friday Nov 08, 2024 by MT Newswires
  12:38PM ET on Friday Nov 08, 2024 by MT Newswires
  Companies Mentioned: MRNA
- Goldman Sachs Adjusts Moderna Price Target to $112 From $130, from 12:37PM ET on Friday Nov 08, 2024 by MT Newswires
  12:37PM ET on Friday Nov 08, 2024 by MT Newswires
  Companies Mentioned: MRNA
- Leerink Partners Adjusts Moderna Price Target to $38 From $46, from 12:37PM ET on Friday Nov 08, 2024 by MT Newswires
  12:37PM ET on Friday Nov 08, 2024 by MT Newswires
  Companies Mentioned: MRNA
- Barclays Adjusts Moderna Price Target to $111 From $125, from 12:36PM ET on Friday Nov 08, 2024 by MT Newswires
  12:36PM ET on Friday Nov 08, 2024 by MT Newswires
  Companies Mentioned: MRNA
- BofA Securities Adjusts Price Target on Moderna to $90 From $110, Maintains Neutral Rating, from 10:34AM ET on Friday Nov 08, 2024 by MT Newswires
  10:34AM ET on Friday Nov 08, 2024 by MT Newswires
  Companies Mentioned: MRNA
- Moderna Says RSV Vaccine Approved by Health Canada for Older Adults, from 8:44AM ET on Friday Nov 08, 2024 by MT Newswires
  8:44AM ET on Friday Nov 08, 2024 by MT Newswires
  Companies Mentioned: MRNA
- Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older, from 7:32AM ET on Friday Nov 08, 2024 by Dow Jones
  7:32AM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: MRNA
- Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma, from 7:30AM ET on Friday Nov 08, 2024 by PR Newswire
  7:30AM ET on Friday Nov 08, 2024 by PR Newswire
  Companies Mentioned: MRNA, CARM

IQVIA Holdings Inc
NYSE:IQVUnited States

Search Criteria

Nov 6, 2024

IQVIA CFO Ron Bruehlman to Speak at the UBS Global Healthcare Conference on November 13, 2024, from 4:15PM ET on Wednesday Nov 06, 2024 by Dow Jones

Argus Cuts Price Target on IQVIA to $260 From $280, from 7:53AM ET on Wednesday Nov 06, 2024 by MT Newswires

Nov 5, 2024

DJ IQVIA Holdings Price Target Maintained With a $270.00/Share by RBC Capital, from 11:34AM ET on Tuesday Nov 05, 2024 by Dow Jones

DJ IQVIA Holdings Is Maintained at Overweight by JP Morgan, from 11:28AM ET on Tuesday Nov 05, 2024 by Dow Jones

JPMorgan Cuts Price Target on IQVIA to $240 From $279, Maintains Overweight Rating, from 7:01AM ET on Tuesday Nov 05, 2024 by MT Newswires

Peers Headlines

Yesterday

S&P 500 Closes Just Shy of Record 6,000 Amid Strong Post-Election Rally, from 20 hours ago by MT Newswires

DJ Moderna Is Maintained at Overweight by Barclays, from 23 hours ago by Dow Jones

Jefferies Adjusts Moderna Price Target to $50 From $55, from 12:38PM ET on Friday Nov 08, 2024 by MT Newswires

Goldman Sachs Adjusts Moderna Price Target to $112 From $130, from 12:37PM ET on Friday Nov 08, 2024 by MT Newswires

Leerink Partners Adjusts Moderna Price Target to $38 From $46, from 12:37PM ET on Friday Nov 08, 2024 by MT Newswires

Barclays Adjusts Moderna Price Target to $111 From $125, from 12:36PM ET on Friday Nov 08, 2024 by MT Newswires

BofA Securities Adjusts Price Target on Moderna to $90 From $110, Maintains Neutral Rating, from 10:34AM ET on Friday Nov 08, 2024 by MT Newswires

Moderna Says RSV Vaccine Approved by Health Canada for Older Adults, from 8:44AM ET on Friday Nov 08, 2024 by MT Newswires

Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older, from 7:32AM ET on Friday Nov 08, 2024 by Dow Jones

Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma, from 7:30AM ET on Friday Nov 08, 2024 by PR Newswire